Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer-Reference-Cited by-同舟云学术

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Published:2013-12-18 Issue:216 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Yasuda Hiroyuki¹²,Park Eunyoung³,Yun Cai-Hong⁴,Sng Natasha J.¹,Lucena-Araujo Antonio R.¹,Yeo Wee-Lee¹,Huberman Mark S.¹,Cohen David W.¹,Nakayama Sohei¹,Ishioka Kota²,Yamaguchi Norihiro¹,Hanna Megan³⁵,Oxnard Geoffrey R.³⁶,Lathan Christopher S.³⁶,Moran Teresa⁷,Sequist Lecia V.⁷,Chaft Jamie E.⁸,Riely Gregory J.⁸,Arcila Maria E.⁸,Soo Ross A.⁹,Meyerson Matthew³⁵⁶,Eck Michael J.³,Kobayashi Susumu S.¹,Costa Daniel B.¹

Affiliation:

1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

2. Keio University Medical School, Tokyo 160-8582, Japan.

3. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

4. Peking University Health Science Center, Beijing 100191, China.

5. Broad Institute, Massachusetts Institute of Technology and Harvard Medical School, Boston, MA 02142, USA.

6. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

7. Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

8. Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA.

9. Cancer Science Institute of Singapore and National University Cancer Institute, National University of Singapore, Singapore 117599, Singapore.

Abstract

Crystal structure and detailed analysis of different EGFR mutants explain why some mutations in exon 20 make lung cancers resistant to EGFR inhibitors and others make them more sensitive.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference70 articles.

1. Cancer statistics, 2013

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

4. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

5. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

Cited by 421 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives;Cancer Treatment Reviews;2024-03

2. A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition;npj Precision Oncology;2024-01-05

3. Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors;Bioorganic Chemistry;2024-01

4. The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors;JTO Clinical and Research Reports;2024-01

5. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review;Medicine;2023-12-29